As April 1 force majeure deadlines passed for several global suppliers, U.S. health systems are entering a critical monitoring phase. While the Strait of Hormuz remains closed, major shortages have not yet materialized domestically, the underlying risks to medical supplies, devices and pharmaceuticals are mounting.
For hospital leaders, the situation is not yet disruptive, but it is increasingly fragile.
Pharmaceuticals: Limited U.S. impact, but rising global strain
So far, U.S. drug supply remains relatively stable. However, global warning signs are increasing:
- International health systems report growing medicine shortages and delays
- Humanitarian and commercial pharmaceutical shipments are facing bottlenecks
The risk to the U.S. is indirect but significant. Generic drugs, which make up roughly 90% of U.S. prescriptions, depend heavily on manufacturing in India and China, both of which rely on stable energy markets and global shipping routes tied to the Middle East. Cold-chain products that are shipped via air freight, including biologics and specialty drugs, are particularly vulnerable to delays due to tight delivery windows and handling requirements.
Medical devices and supplies: Cost pressures are already building
For devices and consumables, U.S. health systems are more likely to feel early impact through pricing and procurement challenges.
Key exposure points include:
- Petroleum-based inputs used in plastics, syringes and tubing
- Global freight costs for bulky equipment
- Lean inventories across distributors and providers
Industry analysis suggests prolonged disruption could drive higher prices and longer lead times for a range of medical products. This is especially relevant for systems already operating on thin margins, where even modest supply inflation can have outsized financial impact.
Force majeure signals a shift in risk
The April 1 force majeure declarations do not necessarily mean immediate shortages. Instead, they represent a structural shift in how risk is being distributed across the supply chain.
Suppliers are effectively signaling:
- Delivery guarantees may not hold
- Costs are likely to increase
- Contract terms may be revisited
For U.S. health systems, this creates uncertainty even before physical shortages emerge.
Key takeaways for health system leaders
- Act early, not reactively
Use this window to assess vulnerabilities before shortages emerge - Prioritize critical supplies
Focus on high-acuity drugs, IV products and essential consumables - Engage supply chain partners now
Clarify contingency plans tied to force majeure declarations - Prepare for sustained cost pressure
Expect increases in freight, energy and device pricing - Collaborate regionally
Shared visibility and coordination can reduce localized disruption
For now, U.S. health systems are insulated from the most severe impacts of the Iran conflict. But the system is under pressure. The combination of force majeure declarations, rising logistics costs and global supply chain stress suggests that disruption, if it comes, will likely arrive gradually rather than all at once.
Leaders who act during this early phase will be better positioned to manage both operational and financial risk in the months ahead.